SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomas
The use of Immunotherapy after first line in advanced gastroesophageal adenocarcinomas
Date
24 Oct 2020Session
SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomasPresenters
E. Smyth, UKResources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
First line treatment for HER2 non amplified advanced gastroesophageal adenocarcinomas
Presenter: F. Lordick, DE
Session: SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomas
Resources:
Slides
Webcast
Treatment for HER2 amplified and advanced gastroesophageal adenocarcinomas
Presenter: A. Cervantes, ES
Session: SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomas
Resources:
Slides
Webcast
Second line treatment and beyond for advanced gastroesophageal adenocarcinomas (including chemo and targeted agents)
Presenter: M. Alsina, ES
Session: SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomas
Resources:
Slides
Webcast
Looking for precision medicine in advanced gastroesophageal adenocarcinomas
Presenter: V. Gambardella, ES
Session: SESSION 3 - Treatment for advanced gastroesophageal adenocarcinomas
Resources:
Slides
Webcast
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.